Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

CDI Launching iPS Cells For Screening

By R&D Editors | March 11, 2010

Cellular Dynamics International is announcing the launch of the first human cells derived from induced pluripotent stem cells (iPSCs) for use in screening new drug candidates for drug toxicity and for drug discovery.  iCell Cardiomyocytes mimic the biochemical and electrophysiological activity of normal human heart muscle cells.  They also beat in culture.  This is important for both pharmaceutical companies and patients because current models for toxicity screening and drug discovery are either animal cells, human cancer cell lines or cells from cadaveric tissue.  None of these accurately mimic normal cells the  way that iCell Cardiomyocytes do.  This has resulted in the launch of drugs, terfenidine and cisapride are two examples, that have caused patient deaths due to cardiotoxicity that was not identified in preclinical testing.  iCell Cardiomyocytes should reduce this risk.  Following extensive validation testing, both internally and with pharmaceutical customers (ex. Roche), the cells are ready for commercial use.

CDI has also accomplished an essential step for the commercial use of stem cells that many talk about but have not yet done.  They have industrialized the process of making both iPSCs and iCell Cardiomyocytes so that CDI makes billions of cells on a weekly basis.  CDI also provides the cells at an exceptionally high purity (>98%).  Drug companies require large and consistent numbers of differentiated cells at high purity to be able to be able to use them in their discovery and toxicity screening systems.  CDI is the only company to yet accomplish this task.

Cellular Dynamics International

Related Articles Read More >

PerkinElmer participating at Bio-IT World Conference & Expo
Nalu Medical’s mIPG is focus of Episode 7 of R&D 100 – The Podcast
R&D 100 winner of the day: Portable EnGineered Analytic Sensor with aUtomated Sampling (PEGASUS)
UCLA bioengineers develop new class of human-powered bioelectronics
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars